|
1
|
El-Serag HB, Mason AC and Key C: Trends in
survival of patients with hepatocellular carcinoma between 1977 and
1996 in the United States. Hepatology. 33:62–65. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
4
|
Carr BI: Hepatocellular carcinoma: current
management and future trends. Gastroenterology. 127:S218–S224.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takenaka Y, Fukumori T and Raz A:
Galectin-3 and metastasis. Glycoconj J. 19:543–549. 2004.
View Article : Google Scholar
|
|
6
|
Radosavljevic G, Volarevic V, Jovanovic I,
et al: The roles of Galectin-3 in autoimmunity and tumor
progression. Immunol Res. 52:100–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saussez S, Camby I, Toubeau G and Kiss R:
Galectins as modulators of tumor progression in head and neck
squamous cell carcinomas. Head Neck. 29:874–884. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McCubrey JA, Steelman LS, Abrams SL, et
al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in
malignant transformation and drug resistance. Adv Enzyme Regul.
46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wesley UV, Vemuganti R, Ayvaci ER and
Dempsey RJ: Galectin-3 enhances angiogenic and migratory potential
of microglial cells via modulation of integrin linked kinase
signaling. Brain Res. 1496:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Friedrichs J, Manninen A, Muller DJ and
Helenius J: Galectin-3 regulates integrin alpha2beta1-mediated
adhesion to collagen-I and -IV. J Biol Chem. 283:32264–32272. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Piccolo E, Tinari N, Semeraro D, et al:
LGALS3BP, lectin galactoside-binding soluble 3 binding protein,
induces vascular endothelial growth factor in human breast cancer
cells and promotes angiogenesis. J Mol Med. 91:83–94. 2013.
View Article : Google Scholar
|
|
12
|
Nangia-Makker P, Wang Y, Raz T, et al:
Cleavage of galectin-3 by matrix metalloproteases induces
angiogenesis in breast cancer. Int J Cancer. 127:2530–2541. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rossi ED, Straccia P, Palumbo M, et al:
Diagnostic and prognostic role of HBME-1, galectin-3, and
beta-catenin in poorly differentiated and anaplastic thyroid
carcinomas. Appl Immunohistochem Mol Morphol. 21:237–241.
2013.PubMed/NCBI
|
|
14
|
Yamaki S, Fujii T, Yajima R, et al:
Clinicopathological significance of decreased galectin-3 expression
and the long-term prognosis in patients with breast cancer. Surg
Today. 43:901–905. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cui W, Sang W, Zheng S, et al: Usefulness
of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1
in the diagnosis of benign and malignant thyroid nodules. Clin Lab.
58:673–680. 2012.PubMed/NCBI
|
|
16
|
Blanquart C, Gueugnon F, Nguyen JM, et al:
CCL2, galectin-3, and SMRP combination improves the diagnosis of
mesothelioma in pleural effusions. J Thorac Oncol. 7:883–889. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paunovic I, Isic T, Havelka M, et al:
Combined immunohistochemistry for thyroid peroxidase, galectin-3,
CK19 and HBME-1 in differential diagnosis of thyroid tumors. APMIS.
120:368–379. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chiu CG, Strugnell SS, Griffith OL, et al:
Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol.
176:2067–2081. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Matsuda Y, Yamagiwa Y, Fukushima K, Ueno Y
and Shimosegawa T: Expression of galectin-3 involved in prognosis
of patients with hepatocellular carcinoma. Hepatol Res.
38:1098–1111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Baldini E, Sorrenti S, D’Armiento E, et
al: The urokinase plasminogen activating system in thyroid cancer:
clinical implications. G Chir. 33:305–310. 2012.PubMed/NCBI
|
|
21
|
Laerum OD, Ovrebo K, Skarstein A, et al:
Prognosis in adenocarcinomas of lower oesophagus,
gastro-oesophageal junction and cardia evaluated by
uPAR-immunohistochemistry. Int J Cancer. 131:558–569. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jacobsen B and Ploug M: The urokinase
receptor and its structural homologue C4.4A in human cancer:
expression, prognosis and pharmacological inhibition. Curr Med
Chem. 15:2559–2573. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Smith HW and Marshall CJ: Regulation of
cell signalling by uPAR. Nat Rev Mol Cell Biol. 11:23–36. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dass K, Ahmad A, Azmi AS, Sarkar SH and
Sarkar FH: Evolving role of uPA/uPAR system in human cancers.
Cancer Treat Rev. 34:122–136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mani T, Wang F, Knabe WE, et al:
Small-molecule inhibition of the uPAR. uPA interaction: Synthesis,
biochemical, cellular, in vivo pharmacokinetics and efficacy
studies in breast cancer metastasis. Bioorg Med Chem. 21:2145–2155.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lebeau AM, Duriseti S, Murphy ST, et al:
Targeting uPAR with antagonistic recombinant human antibodies in
aggressive breast cancer. Cancer Res. 73:2070–2081. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Soydinc HO, Duranyildiz D, Guney N, Derin
D and Yasasever V: Utility of serum and urine uPAR levels for
diagnosis of breast cancer. Asian Pac J Cancer Prev. 13:2887–2889.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park JS, Park JH, Khoi PN, Joo YE and Jung
YD: MSP-induced RON activation upregulates uPAR expression and cell
invasiveness via MAPK, AP-1 and NF-kappaB signals in gastric cancer
cells. Carcinogenesis. 32:175–181. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baek MK, Park JS, Park JH, et al:
Lithocholic acid upregulates uPAR and cell invasiveness via MAPK
and AP-1 signaling in colon cancer cells. Cancer Lett. 290:123–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoon SY, Lee YJ, Seo JH, et al: uPAR
expression under hypoxic conditions depends on iNOS modulated ERK
phosphorylation in the MDA-MB-231 breast carcinoma cell line. Cell
Res. 16:75–81. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bessard A, Fremin C, Ezan F, Coutant A and
Baffet G: MEK/ERK-dependent uPAR expression is required for
motility via phosphorylation of P70S6K in human hepatocarcinoma
cells. J Cell Physiol. 212:526–536. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu KL, Huang EY, Jhu EW, et al:
Overexpression of galectin-3 enhances migration of colon cancer
cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J
Gastroenterol. 48:350–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Song S, Ji B, Ramachandran V, et al:
Overexpressed galectin-3 in pancreatic cancer induces cell
proliferation and invasion by binding Ras and activating Ras
signaling. PLoS One. 7:e426992012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weng CJ, Tsai CM, Chen YC, et al:
Evaluation of the association of urokinase plasminogen activator
system gene polymorphisms with susceptibility and pathological
development of hepatocellular carcinoma. Ann Surg Oncol.
17:3394–3401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nangia-Makker P, Nakahara S, Hogan V and
Raz A: Galectin-3 in apoptosis, a novel therapeutic target. J
Bioenerg Biomembr. 39:79–84. 2007. View Article : Google Scholar
|
|
36
|
Fukumori T, Kanayama HO and Raz A: The
role of galectin-3 in cancer drug resistance. Drug Resist Updat.
10:101–108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song YK, Billiar TR and Lee YJ: Role of
galectin-3 in breast cancer metastasis: involvement of nitric
oxide. Am J Pathol. 160:1069–1075. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bresalier RS, Yan PS, Byrd JC, Lotan R and
Raz A: Expression of the endogenous galactose-binding protein
galectin-3 correlates with the malignant potential of tumors in the
central nervous system. Cancer. 80:776–787. 1997. View Article : Google Scholar
|
|
39
|
Cvejic DS, Savin SB, Petrovic IM, et al:
Galectin-3 expression in papillary thyroid carcinoma: relation to
histomorphologic growth pattern, lymph node metastasis,
extrathyroid invasion, and tumor size. Head Neck. 27:1049–1055.
2005. View Article : Google Scholar
|
|
40
|
John CM, Leffler H, Kahl-Knutsson B,
Svensson I and Jarvis GA: Truncated galectin-3 inhibits tumor
growth and metastasis in orthotopic nude mouse model of human
breast cancer. Clin Cancer Res. 9:2374–2383. 2003.PubMed/NCBI
|
|
41
|
Kobayashi T, Shimura T, Yajima T, et al:
Transient gene silencing of galectin-3 suppresses pancreatic cancer
cell migration and invasion through degradation of beta-catenin.
Int J Cancer. 129:2775–2786. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Alge-Priglinger CS, Andre S, Schoeffl H,
et al: Negative regulation of RPE cell attachment by
carbohydrate-dependent cell surface binding of galectin-3 and
inhibition of the ERK-MAPK pathway. Biochimie. 93:477–488. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shalom-Feuerstein R, Cooks T, Raz A and
Kloog Y: Galectin-3 regulates a molecular switch from N-Ras to
K-Ras usage in human breast carcinoma cells. Cancer Res.
65:7292–7300. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Boscher C and Nabi IR: Galectin-3- and
phospho-caveolin-1-dependent outside-in integrin signaling mediates
the EGF motogenic response in mammary cancer cells. Mol Biol Cell.
24:2134–2145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Santiago-Gomez A, Barrasa JI, Olmo N, et
al: 4F2hc-silencing impairs tumorigenicity of HeLa cells via
modulation of galectin-3 and beta-catenin signaling, and MMP-2
expression. Biochim Biophys Acta. 1833:2045–2056. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sant’ana JM, Chammas R, Liu FT, et al:
Activation of the Wnt/beta-catenin signaling pathway during oral
carcinogenesis process is not influenced by the absence of
galectin-3 in mice. Anticancer Res. 31:2805–2811. 2011.PubMed/NCBI
|
|
47
|
Dakeng S, Duangmano S, Jiratchariyakul W,
et al: Inhibition of Wnt signaling by cucurbitacin B in breast
cancer cells: reduction of Wnt-associated proteins and reduced
translocation of galectin-3-mediated beta-catenin to the nucleus. J
Cell Biochem. 113:49–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kwaan HC and McMahon B: The role of
plasminogen-plasmin system in cancer. Cancer Treat Res. 148:43–66.
2009. View Article : Google Scholar
|
|
49
|
Zheng Q, Tang ZY, Xue Q, et al: Invasion
and metastasis of hepatocellular carcinoma in relation to
urokinase-type plasminogen activator, its receptor and inhibitor. J
Cancer Res Clin Oncol. 126:641–646. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Falasca M: PI3K/Akt signalling pathway
specific inhibitors: a novel strategy to sensitize cancer cells to
anti-cancer drugs. Curr Pharm Des. 16:1410–1416. 2010. View Article : Google Scholar : PubMed/NCBI
|
